サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179873

インスリン抵抗性の世界市場-2023-2030

Global Insulin Resistance Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
インスリン抵抗性の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

インスリン抵抗性の世界市場規模は、予測期間中（2023-2030年）にCAGR4.2％で成長するとされています。

インスリン抵抗性は、正常なインスリン濃度に対する生理的反応が異常に遅くなることです。筋肉、脂肪、肝臓の細胞がインスリンにうまく反応せず、血液中のグルコースをエネルギーとして利用できない状態をインスリン抵抗性と呼びます。その結果、膵臓はより多くのインスリンを産生するようになります。血糖値は時間の経過とともに上昇します。2型糖尿病、コレステロール、血圧、肥満などは、インスリン抵抗性症候群の一例です。

市場力学

世界のインスリン抵抗性市場を牽引する主な要因は、座りがちなライフスタイルの増加と糖尿病罹患率の拡大です。また、保険償還やその他の価格関連の政府規制が市場を牽引し、ヘルスケア部門の成長と最先端の医療処置に関する一般市民の知識の向上が市場を推進すると考えられます。

座りがちなライフスタイルの拡大と糖尿病有病率の拡大

インスリン抵抗性の市場は、座りがちなライフスタイルの増加や糖尿病罹患率の上昇により拡大しています。高齢化、座りがちなライフスタイルの増加、肥満の増加により、インスリン抵抗性患者の増加が予想されます。また、座りがちな生活習慣の定着や身体活動の低下により、その懸念はますます高まっています。ブドウ糖負荷試験は、ブドウ糖を投与した後に採血を行い、体内からどれだけ早く排出されるかを評価するものです。一般的には、糖尿病、インスリン抵抗性、β細胞活性の低下、反応性低血糖、先端巨大症、その他のあまり一般的ではない糖質代謝異常の有無を確認するための検査として行われます。

国際糖尿病連合によると、2021年までに成人（20～79歳）の糖尿病患者数は5億3700万人と推計されています。また、2030年には6億4,300万人、2045年には7億8,300万人が糖尿病を患い、4人に3人が低・中所得国に居住していると推定されています。成人の糖尿病患者数は、ほぼ2人に1人（2億4,000万人）となっています。市場は、世界の糖尿病罹患率の上昇に牽引されています。

医薬品の選択肢が限られていること、インスリン抵抗性に関する情報が不足していることが市場成長の妨げになると予想されます。

利用可能な医薬品が少ないことや、インスリン抵抗性に関する知識の不足は、インスリン抵抗性市場の成長を妨げると予想される要因の一部です。さらに、この業界は発展途上国や新興国においてより多くの償還を必要としています。

COVID-19の影響分析

パンデミックは、世界の財務的な期待、業務、危機対応戦略にマイナスの影響を及ぼしています。COVID-19による重篤な疾患を発症するリスクの増加は、特定の基礎的な医学的障害を持つ個人に存在する可能性があります。糖尿病、心臓疾患、肥満、慢性腎臓病がその例です。CDCの特定の研究によると、2型糖尿病患者はCOVID-19関連の重篤な病気を発症するリスクが高くなりました。COVID-19の大流行により、アクセシビリティとアフォーダビリティの優先順位が上がり、それは糖尿病患者の開発戦略にも影響を及ぼしました。

パンデミック時に患者がインスリンを入手するのを支援するため、米国市場で事業を展開する多数の製薬会社がプログラムを公開しました。COVID-19の流行による社会経済的な影響から、多くの糖尿病患者がヘルスケアにアクセスできない可能性があるとき。製薬会社は、インスリンや抗糖尿病薬への需要が高まるため、糖尿病患者にとって新規性の高い、よりアプローチしやすい治療法を生み出すチャンスが高まります。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 座りがちなライフスタイルの増加、糖尿病罹患率の拡大
      • 保険償還や価格に関する政府規制も市場を牽引
    • 抑制要因
      • 薬剤の選択肢の少なさ、インスリン抵抗性に関する情報の不足
    • ビジネスチャンス
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 薬物クラス別

  • ビグアナイド系
  • グルカゴン様ペプチド1（GLP-1）受容体アゴニスト
  • 濃縮インスリン製剤
  • ナトリウムグルコースコトランスポーター2（SGLT2）阻害剤
  • ジペプチジルペプチダーゼ-4（DPP-4）阻害剤
  • その他

第8章 薬剤タイプ別

  • ブランド
  • ジェネリック医薬品

第9章 流通チャネル別

  • 病院内薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • Glenmark Pharmaceuticals
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Merck & Co.
  • Nova Nordisk
  • Teva Pharmaceuticals
  • Sanofi
  • GlaxoSmithKline
  • Mylan.

第13章 インスリン抵抗性の世界市場-DataM

目次
Product Code: DMPH23

Market Overview

The Global Insulin Resistance Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 4.2% during the forecast period (2023-2030).

Insulin resistance is an abnormally slow physiologic reaction to normal insulin concentrations. When cells in the muscles, fat, and liver do not respond to insulin well and cannot utilize glucose from the blood for energy, this condition is known as insulin resistance. The pancreas produces more insulin as a result. Blood sugar levels rise over time. Type 2 diabetes, cholesterol, blood pressure, and obesity are just a few of the conditions that are a part of insulin resistance syndrome.

Market Dynamics

The major factors driving the global insulin resistance market are the growing sedentary lifestyle and expanding diabetes prevalence, the market will also be driven by reimbursement and other pricing-related government regulations, and the growing healthcare sector and increased public knowledge of cutting-edge medical procedures will propel the market.

Growing sedentary lifestyle and expanding diabetes prevalence.

The market for insulin resistance is expanding as a result of rising sedentary lifestyles and rising diabetes prevalence. Patients with insulin resistance are expected to increase due to an aging population, an increase in sedentary lifestyles, and an increase in obesity incidence. Concerns are increased by sedentary lifestyle adoption and a decline in physical activity. In the glucose tolerance test, blood samples are taken after glucose is administered to assess how rapidly it is eliminated from the body. Typically, the test is used to check for diabetes, insulin resistance, decreased beta cell activity, reactive hypoglycemia, acromegaly, and other less common abnormalities of carbohydrate metabolism.

According to International Diabetes Federation estimates that 537 million adults (20-79 years old) will have diabetes by 2021. By 2030, there will be 643 million people worldwide living with diabetes, and by 2045, there will be 783 million; 3 in 4 individuals with diabetes reside in low- and middle-income nations. Adults with diabetes make up almost one in two people (240 million). The market is driven by the rising prevalence of diabetes globally.

Limited pharmaceutical choices and lack of information on insulin resistance is expected to hamper the market's growth.

The availability of few medications and the lack of knowledge about insulin resistance are some of the factors expected to hinder the growth of the insulin resistance market. Additionally, the industry needs more reimbursement in developing and rising nations.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. An increased risk of developing a serious disease from COVID-19 may exist in individuals with specific underlying medical disorders. Diabetes, cardiac issues, obesity, and chronic kidney disease are some ailments. According to a CDC specific study, type 2 diabetes patients had a higher risk of developing severe COVID-19-related illnesses, according to the CDC. Accessibility and affordability have increased in priority due to the COVID-19 pandemic, which also affected diabetic developer strategies.

To assist patients in getting insulin during the pandemic, numerous pharmaceutical companies operating in the US market have publicly publicized programs. When many diabetes patients may not have access to healthcare due to the socio-economic impact of the COVID-19 epidemic. Drug manufacturers have a greater chance to produce novel and more approachable therapies for the diabetic population due to the increased demand for insulin and anti-diabetics.

Segment Analysis

Concentrated insulin products of Insulin resistance the segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Over the past few years, there have been more concentrated insulin products available in the US to treat diabetic patients. These medications may give patients options to improve glycemic control with treatment regimens that may increase their adherence to therapy since they contain more units of insulin per milliliter than typical U-100 insulins. All concentrated insulins are offered in distinctive prefilled pen devices that make it easy to identify the product and administer doses precisely.

Recent developments in concentrated insulins (exceeding 100 units/mL) and specialized equipment have given persons with diabetes new treatment choices for basal and prandial insulin supplementation. The concentrations of concentrated insulin formulations range from 2-fold (insulin lispro 200 units/mL), which has a fast-acting prandial effect, to 5-fold (human regular insulin 500 units/mL), which has basal and short-acting prandial activities. Degludec 200 units/mL and glargine 300 units/mL are two long-acting basal insulins. Concentrated insulins were created with the intention of simplifying the administration of insulin by lowering the volume and frequency of injections and, in certain cases, by utilizing modified pharmacokinetic and pharmacodynamic features. The market is driven by the development of the product and its use.

Geographical Analysis

North America holds the largest market share in the global Insulin resistance market.

Nearly 40% of young adults without diabetes, according to research from the University of Alabama at Birmingham in 2021, have insulin resistance, a disease in which the body does not respond to insulin as it should and cannot use blood glucose for energy. In the United States, where nearly 50% of the earnings for the manufacturers of insulin come from within the nation, the cost aspect is the biggest concern.

Under the direction of the Institute of Nutrition, Metabolism, and Diabetes, the Canadian Institutes of Health Research is funding cutting-edge research into diabetes (CIHR-INMD). 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes is a significant initiative that the Institute launched in 2019 to increase funding for Canadian researchers so they can work with collaborators to find novel approaches to preventing and treating diabetes and its complications. The region's market growth is primarily influenced by powerful market rivals, increasing healthcare GDP spending, and improved government reimbursement for insulin treatment.

Competitive Landscape

The insulin resistance market is moderately competitive with local and global companies' presence Glenmark Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Merck & Co., Nova Nordisk, Teva Pharmaceuticals, Sanofi, GlaxoSmithKline, Mylan and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in October 2022, Glenmark Pharmaceuticals announced the introduction of Thiazolidinedione Lobeglitazone for the treatment of type 2 diabetes in adults. According to a statement from Glenmark Pharmaceuticals, there is a high frequency of insulin resistance among Indians, making LOBG an appealing treatment option for treating insulin-resistant diabetic patients with uncontrolled Type 2 diabetes

Glenmark Pharmaceuticals.

Overview: Glenmark Pharmaceuticals Ltd. (Glenmark) 's primary objective is developing novel chemical entities (NCEs). The company creates and sells both branded and generic formulations. Oncology, dermatology, and respiratory are just a few therapeutic specialties covered by the company's formulations division. Additionally, it is used in numerous therapeutic contexts, including oral contraceptives, diabetes, and cardiovascular conditions. The firm produces and distributes active medicinal components (APIs). Glenmark has production sites in the Czech Republic, the United States, Argentina, and India.

Product Portfolio:

LOBG: Thiazolidinedione Drug called lobeglitazone that increases insulin sensitivity The anti-diabetic drug will be offered for sale under the trade name LOBG . It has 0.5 mg of lobeglitazone and should be taken one daily as directed. LOBG is a desirable medical alternative for patients with Type 2 diabetes who are insulin resistant.

The global Insulin resistance market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing sedentary lifestyle and expanding diabetes prevalence
      • 4.1.1.2. The market will also be driven by reimbursement and other pricing-related government regulations
    • 4.1.2. Restraints:
      • 4.1.2.1. Limited pharmaceutical choices and lack of information on insulin resistance
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Biguanides
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
  • 7.4. Concentrated Insulin Products
  • 7.5. Sodium-glucose cotransporter 2 (SGLT2) inhibitors
  • 7.6. Dipeptidyl peptidase-4 (DPP-4) inhibitor
  • 7.7. Others

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Branded
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Generics

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Glenmark Pharmaceuticals
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca
  • 12.3. Bristol-Myers Squibb
  • 12.4. Eli Lilly and Company
  • 12.5. Merck & Co.
  • 12.6. Nova Nordisk
  • 12.7. Teva Pharmaceuticals
  • 12.8. Sanofi
  • 12.9. GlaxoSmithKline
  • 12.10. Mylan.

LIST NOT EXHAUSTIVE

13. Global Insulin resistance Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us